Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 1, 2022
Event: Entry into a Material Definitive Agreement (Modification No. 13 to Project Agreement No. 01).
Key Financial Metrics
This filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a contractual modification.
Material Changes
The Company executed Modification No. 13 to its Project Agreement with Advanced Technology International (acting for the Medical CBRN Defense Consortium/Operation Warp Speed). Key changes include:
- Inclusion of a Phase 3 efficacy study for the 2019n-CoV-301 vaccine in adolescents.
- Addition of a booster component to the study.
- Extension of the performance period under the Project Agreement to December 31, 2023.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the continuation of the partnership with Operation Warp Speed (OWS), a collaboration between the U.S. Department of Health and Human Services and the U.S. Department of Defense aimed at accelerating COVID-19 vaccine development and distribution.
Risks and Contingencies: The filing notes that the description of the modification is not complete and is qualified by reference to the full Modification document, which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Investor Verification Checklist
- Verify the full text of Modification No. 13 in the upcoming Form 10-K exhibit.
- Confirm the specific financial obligations or funding terms associated with the extended performance period through December 31, 2023.
- Monitor the progress and results of the Phase 3 efficacy study in adolescents.